Novartis drug shows early promise fragile X syndrome

Novartis this week announced results from a small clinical trial of a new drug which could help improve behaviors resulting from fragile X syndrome, an inherited genetic condition that can cause retardation and autism and affects one in 5,000 children. The study involved just a few dozen subjects, and only some of those responded to the therapy, but researchers are excited about any results for a condition that has been impossible to treat. "Just three years ago, I would have said that...